With Boston Scientific Stock Sliding, Have You Assessed The Risk?
Boston Scientific (BSX) stock is down 18.8% in 21 trading days. The recent slide reflects renewed concerns around cautious 2026 guidance and weaker electrophysiology sales, but sharp drops like this often raise a tougher question: is the weakness temporary, or a sign of deeper cracks in the story?
Before judging its downturn reslience, let’s look at where Boston Scientific stands today.
- Size: Boston Scientific is a $111 Bil company with $20 Bil in revenue currently trading at $75.15.
- Fundamentals: Last 12 month revenue growth of 19.9% and operating margin of 19.8%.
- Liquidity: Has Debt to Equity ratio of 0.1 and Cash to Assets ratio of 0.04
- Valuation: Boston Scientific stock is currently trading at P/E multiple of 38.5 and P/EBIT multiple of 29.8
- Has one instance since 2010 where it dipped >30% in < 30 days and subsequently returned 41.1% within a year. See BSX Dip Buy Analysis.
These metrics point to a Strong operational performance, alongside High valuation – making the stock Fairly Priced. For details, see Buy or Sell BSX Stock
That brings us to the key consideration for investors worried about this fall: how resilient is BSX stock if markets turn south? This is where our downturn resilience framework comes in. Suppose BSX stock falls another 20-30% to $53 – can investors comfortably hold on? Turns out, the stock saw an impact slightly worse than the S&P 500 index during various economic downturns, based on (a) how much the stock fell and, (b) how quickly it recovered. Below, we dive deeper into each such downturn.
- Boston Scientific Stock Hits Key Support – Buying Opportunity?
- BSX Stock: Don’t Try To Catch The Falling Knife
- Time To Buy The Dip In Boston Scientific Stock?
- How Low Can BSX Really Go In A Market Crash?
- Is BSX Stock A Value Trap Or A Rebound Play?
- Stronger Bet Than IDEXX Laboratories Stock: DXCM, BSX Deliver More
2022 Inflation Shock
- BSX stock fell 25.2% from a high of $47.10 on 20 April 2022 to $35.24 on 14 June 2022 vs. a peak-to-trough decline of 25.4% for the S&P 500.
- However, the stock fully recovered to its pre-Crisis peak by 12 December 2022
- Since then, the stock increased to a high of $108.14 on 8 September 2025 , and currently trades at $75.15
| BSX | S&P 500 | |
|---|---|---|
| % Change from Pre-Recession Peak | -25.2% | -25.4% |
| Time to Full Recovery | 181 days | 464 days |
2020 Covid Pandemic
- BSX stock fell 43.5% from a high of $45.71 on 9 January 2020 to $25.83 on 23 March 2020 vs. a peak-to-trough decline of 33.9% for the S&P 500.
- However, the stock fully recovered to its pre-Crisis peak by 2 August 2021
| BSX | S&P 500 | |
|---|---|---|
| % Change from Pre-Recession Peak | -43.5% | -33.9% |
| Time to Full Recovery | 497 days | 148 days |
2018 Correction
- BSX stock fell 18.7% from a high of $39.04 on 2 October 2018 to $31.73 on 24 December 2018 vs. a peak-to-trough decline of 19.8% for the S&P 500.
- However, the stock fully recovered to its pre-Crisis peak by 8 February 2019
| BSX | S&P 500 | |
|---|---|---|
| % Change from Pre-Recession Peak | -18.7% | -19.8% |
| Time to Full Recovery | 46 days | 120 days |
2008 Global Financial Crisis
- BSX stock fell 70.5% from a high of $18.59 on 30 January 2007 to $5.48 on 20 November 2008 vs. a peak-to-trough decline of 56.8% for the S&P 500.
- However, the stock fully recovered to its pre-Crisis peak by 2 November 2015
| BSX | S&P 500 | |
|---|---|---|
| % Change from Pre-Recession Peak | -70.5% | -56.8% |
| Time to Full Recovery | 2,538 days | 1,480 days |
Feeling jittery about BSX stock? Consider portfolio approach.
Smart Investing Begins With Portfolios
Stocks can jump or crash but long term success comes from staying invested. The right portfolio helps you ride gains and cushion single stock drops.
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? HQ Portfolio has posted more than 105% in cumulative return since inception, with less risk versus the benchmark index, as evident in HQ Portfolio performance metrics.